IP Library › Granted Patent US 12,692,314
Granted Patent B2
US 12,692,314 · App. 18/312,519 · Granted Jul 28, 2026

CD3/BCMA/CD38 trispecific antibodies

Inventors: Maria Pihlgren Bosch (La Chaux-de-Fonds, CH); Mario Perro (La Chaux-de-Fonds, CH); Olivia Hall (La Chaux-de-Fonds, CH); Laura Carretero Iglesia (La Chaux-de-Fonds, CH); Adam Drake (La Chaux-de-Fonds, CH); Daniela Pais (La Chaux-de-Fonds, CH); Rebecca Croasdale-Wood (La Chaux-de-Fonds, CH); Carole Estoppey (La Chaux-de-Fonds, CH); Michael Dyson (La Chaux-de-Fonds, CH); Thierry Monney (La Chaux-de-Fonds, CH)
Assignee: IGI THERAPEUTICS SA
C07K16/2809A61P35/00C07K16/2878C07K16/2896C07K2317/31C07K2317/515C07K2317/55C07K2317/565C07K2317/622C07K2317/70C07K2317/71C07K2317/72C07K2317/76C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,692,314
App. No.
18/312,519
Filed
May 4, 2023
Granted
Jul 28, 2026
Kind
B2
Art Unit
1643
USPC
424/136.1
Abstract

The present invention relates to novel trispecific heterodimeric immunoglobulins. More specifically the present invention relates to trispecific heterodimeric immunoglobulins that target human CD3 antigen, human BCMA and human CD38 antigen. The present invention also relates to this novel class of trispecific heterodimeric immunoglobulins for use in the treatment of proliferative diseases and in particular cancers such as hematological cancer. The present invention relates to novel trispecific antibody for use in treating multiple myeloma.

Claims (18)

1 . A trispecific antibody that binds to human CD3, human B-cell maturation antigen (BCMA), and human CD38, comprising:

a. a first heavy chain polypeptide, said first heavy chain polypeptide comprising

i. a first heavy chain variable domain comprising a CDR1 having the amino acid sequence shown as SEQ ID NO: 181, a CDR2 having the amino acid sequence shown as SEQ ID NO: 307, and a CDR3 having the amino acid sequence shown as SEQ ID NO: 433, and

ii. a second heavy chain variable domain comprising a CDR1 having the amino acid sequence shown as SEQ ID NO: 234, a CDR2 having the amino acid sequence shown as SEQ ID NO: 360, and a CDR3 having the amino acid sequence shown as SEQ ID NO: 486; and

b. a second heavy chain polypeptide, said second heavy chain polypeptide comprising a heavy chain variable domain comprising a CDR1 having the amino acid sequence shown as SEQ ID NO: 239, a CDR2 having the amino acid sequence shown as SEQ ID NO: 365, and a CDR3 having the amino acid sequence shown as SEQ ID NO: 491; and

c. three light chain polypeptides, each of said light chain polypeptides comprising a light chain variable domain comprising a CDR1 having the amino acid sequence shown as SEQ ID NO: 721, a CDR2 having the amino acid sequence shown as SEQ ID NO: 722, and a CDR3 having the amino acid sequence shown as SEQ ID NO: 723.

2 . The trispecific antibody of claim 1 , wherein the second heavy chain variable domain of the first heavy chain polypeptide is fused at the N-terminus to the C-terminus of the first heavy chain variable domain of the first heavy chain polypeptide via a peptide linker.

3 . The trispecific antibody of claim 1 , wherein said trispecific antibody comprises a non-naturally occurring Fc domain.

4 . The trispecific antibody of claim 1 , wherein one heavy chain polypeptide comprises a first engineered IgG1 CH3 domain and the other heavy chain polypeptide comprises a second engineered IgG1 CH3 domain, wherein said first engineered IgG1 CH3 domain comprises all of the substitutions of the group consisting of: Q347A, S364K, T366V, K370T, K392Y, F405S, Y407V, K409W, and T411 N according to EU numbering, and said second engineered IgG1 CH3 domain comprises all of the substitutions of the group consisting of: Q347E, Y349A, L351 F, S364T, T366V, K370T, T394D, V397L, D399E, F405A, Y407S, K409R, and T411R according to EU numbering.

5 . The trispecific antibody of claim 1 , wherein two of the three light chain polypeptides are covalently linked via disulfide bonding to the first heavy chain polypeptide and the third light chain polypeptide is covalently linked via disulfide bonding to the second heavy chain polypeptide.

6 . The trispecific antibody of claim 1 , wherein the first heavy chain polypeptide comprises a first heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO: 592.

7 . The trispecific antibody of claim 1 , wherein the first heavy chain polypeptide comprises a second heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO: 591.

8 . The trispecific antibody of claim 1 , wherein the second heavy chain polypeptide comprises a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO: 594.

9 . The trispecific antibody of claim 1 , wherein the first heavy chain polypeptide comprises a first heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO: 592, the first heavy chain polypeptide comprises a second heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO: 591, and the second heavy chain polypeptide comprises a heavy chain variable domain comprising the amino acid sequence shown as SEQ ID NO: 594.

10 . A trispecific antibody that binds to human CD3, human BCMA, and human CD38, comprising:

(i) a first polypeptide comprising the amino acid sequence shown as SEQ ID NO: 546;

(ii) a second polypeptide comprising the amino acid sequence shown as SEQ ID NO: 547; and

(iii) a third, a fourth, and a fifth polypeptide each comprising the amino acid sequence shown as SEQ ID NO: 1.

Assignments (2)
CHANGE OF NAME Recorded Aug 25, 2025
From: ICHNOS SCIENCES SA
To: IGI THERAPEUTICS SA
Reel/Frame 072111/0007 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 3, 2024
From: PIHLGREN BOSCH, MARIA; PERRO, MARIO; HALL, OLIVIA; CARRETERO IGLESIA, LAURA; DRAKE, ADAM; PAIS, DANIELA; CROASDALE WOOD, REBECCA; LOYAU, JÉRÉMY; ESTOPPEY, CAROLE; SRIVASTAVA, ANKITA; DYSON, MICHAEL; MACOIN, JULIE; CHIMEN, MYRIAM; MONNEY, THIERRY; DREYFUS, CYRILLE
To: ICHNOS SCIENCES SA
Reel/Frame 067910/0577 →
Priority Claims (4)
EP 22172090 · May 6, 2022 · regional
EP 22186879 · Jul 26, 2022 · regional
EP 22207756 · Nov 16, 2022 · regional
EP 22212233 · Dec 8, 2022 · regional
Continuity (2)
Related Publication 20240132615A1 · Apr 25, 2024
Related Publication 20240228650A9 · Jul 11, 2024
References Cited (76)
US 8883981B2 · Shitara · 2014 [cited by examiner]
US 9209965B2 · Rahbar et al. · 2015 [cited by applicant]
US 10882922B2 · Yang et al. · 2021 [cited by applicant]
US 11124577B2 · Vu et al. · 2021 [cited by applicant]
US 20170027488A1 · Enenkel et al. · 2017 [cited by applicant]
US 20200048348A1 · Trinklein · 2020 [cited by examiner]
US 20200399386A1 · Abbasian · 2020 [cited by examiner]
US 20210163620A1 · Granda et al. · 2021 [cited by applicant]
US 20210284749A1 · Park · 2021 [cited by examiner]
US 20220089767A1 · Bouchez · 2022 [cited by examiner]
US 20220348659A1 · Sato · 2022 [cited by examiner]
US 20230242656A1 · Li · 2023 [cited by examiner]
US 20250206823A1 · Qu · 2025 [cited by examiner]
WO WO1999051642A1 · 1999 [cited by applicant]
WO WO2012131555A2 · 2012 [cited by applicant]
WO WO2012135345A1 · 2012 [cited by applicant]
WO WO2019195535A1 · 2019 [cited by examiner]
WO WO2020204708A1 · 2020 [cited by applicant]
Blythe (Protein Science (2005) 14:246-248) (Year: 2005). [cited by examiner]
Gershoni (Biodrugs (2007) 21(3): 145-156) (Year: 2007). [cited by examiner]
Sela-Culang (Frontiers in Immunology (2013) 4: 302) (Year: 2013). [cited by examiner]
Almagro (Frontiers in Immunology (2018) 8: 1751) (Year: 2018). [cited by examiner]
Ni (The Protein Journal (2024) 43: 683-696) (Year: 2024). [cited by examiner]
Anderson, K.C., et al., “Clinically relevant end points and new drug approvals for myeloma,” Leukemia. 22(2):231-9, Nature Publishing Group, United Kingdom (Feb. 2008). [cited by applicant]
Arnett, K., et al., “Crystal structure of a human CD3-epsilon/delta dimer in complex with a UCHT1 single-chain antibody fragment,” Proc. Natl. Acad. Sci. USA. 101(46):16268-73, PNAS, United States (Nov. 2004). [cited by applicant]
Bird, R.E., et al., “Single-chain antigen-binding proteins,” Science 242:423-426, American Association for the Advancement of Science, United States (Oct. 1988). [cited by applicant]
Cohen, A.D., et al., “B cell maturation antigen—specific Car T cells are clinically active in multiple myeloma,” The Journal of Clinical Investigation 129:2210-2221, The American Society for Clinical Investigation, Unit… [cited by applicant]
Coloma, M.J., and Morrison, S.L., “Design and production of novel tetravalent bispecific antibodies,” Nat. Biotechnol. 15(2):159-62, Nature Publishing Group, United States (Feb. 1997). [cited by applicant]
Frankel, SR., and Baeuerle, PA., “Targeting T cells to tumor cells using bispecific antibodies,” Current Opinion in Chemical Biology 17(3):385-92, Elsevier, Netherlands (2013). [cited by applicant]
Frerichs. K.A., et al., “Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab,” Clin. Cancer Res. 26(9):2203-2215, American Associat… [cited by applicant]
Hezareh, M., et al., “Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody against Human Immunodeficiency Virus Type 1,” J. Virol. 75(24):12161-12168, American Society for Microbiology, … [cited by applicant]
Hinton, P.R., et al., “An engineered human IgG1 antibody with longer serum half-life,” J. Immunol. 176(1):346-56, American Associated of Immunologists, United States (Jan. 2006). [cited by applicant]
Holliger. P., et al., “‘Diabodies’: small bivalent and bispecific antibody fragments,” Proc. Natl. Acad. Sci. US. 90:6444-48, PNAS, United States (Jul. 1993). [cited by applicant]
Huston, J.S., et al., “Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in [cited by applicant]
Kalim, M., et al., “Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates,” Drug Des. Devel. Ther. 11:2265-2276, Dove Medical Press, New Zealand (Aug. 2017). [cited by applicant]
Laabi, Y.,et al., “A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16) (q26;p13) translocation in a malignant T cell lymphoma,” The EMBO Journal 11(11):3897-3904, Oxford University Press, U… [cited by applicant]
Labrijn, A.F., et al., “Controlled Fab-arm exchange for the generation of stable bispecific IgG1,” Nat. Protoc. 9(10):2450-63, Nature Publishing Group, United Kingdom (Oct. 2014). [cited by applicant]
Ferrero, E.,., et al., “A Natural History of the Human CD38 Gene,” pp. 65-79 in [cited by applicant]
Liu, Y., et al., “High-throughput screening for developability during early-stage antibody discovery using self-interaction nanoparticle spectroscopy,” mABs 6(2):483-92, Landes Bioscience, United States (Apr. 2014). [cited by applicant]
Madry, C., et al., “The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily,” International Immunology 10(11):1693-1702, Oxford University Press, United King… [cited by applicant]
May, C., et al., “Advances in bispecific biotherapeutics for the treatment of cancer,” Biochemical Pharmacology. 84(9):1105-12, Elsevier, Netherlands (2012). [cited by applicant]
Moreau, P., et al., “Teclistamab in Relapsed or Refractory Multiple Myeloma,” The New England Journal of Medicine, 6:495-505, Massachusetts Medical Society, United States (Jun. 2022). [cited by applicant]
Moreaux, J., et al., “BAFF and APRIL protect myeloma cell from apoptosis induced by interleukin 6 deprivation and dexamethasone,” Blood. 103(8):3148-3157, Elsevier, Netherlands (Apr. 2004). [cited by applicant]
Munshi, N.C., et al., “Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma,” The New England Journal of Medicine 384:705-716, Massachusetts Medical Society, United States (Mar. 2021). [cited by applicant]
Nie, S., et al., “Biology drives the discovery of bispecific antibodies as innovative therapeutics,” Antibody Therapeutics 3(1):17-62, National Library of Medicine, United Kingdom (2020). [cited by applicant]
Nijhof, I.S., et al., “CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma,” Blood 128:7, Elsevier, Netherlands (Aug. 2016). [cited by applicant]
Parslow, A.C., et al., “Antibody-Drug Conjugated for Cancer Therapy,” Biomedicines 4(3):14, MDPI, Switzerland (Jul. 2016). [cited by applicant]
Pillarisetti, K., et al., “Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma,” Blood Adv. 4(18):4538-4549, Elsevier, Netherlands (Sep. 2020). [cited by applicant]
Ran, F.A., et al., “Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity,” Cell. 154(6)1380-9, Elsevier, Netherlands (Sep. 2013). [cited by applicant]
Rodriguez-Lobato, L. G., et al., “Why Immunotherapy Fails in Multiple Myeloma,” Hemato. 2(1):1-42, MDPI, Switzerland (Dec. 2020). [cited by applicant]
Schlothauer. T., et al., “Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions,” Protein Eng. Des. Sel. 29(10):457-466, Oxford University Press, United Kingdom (Jul. 201… [cited by applicant]
Seckinger, A., et al., “Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment,” Cancer Cell. 31(3):396-410, Cell Press, Uni… [cited by applicant]
Shields, R.L., et al., “High resolution mapping of the binding site on human IgGI for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgGI variants with improved binding to the Fc gamma R,” J. Biol. Che… [cited by applicant]
Skegro, D., et al., “Immunoglobin domain interface exchange as a platform technology for the generation of Fc heterodimers and bispecific antibodies,” J. Biol. Chem. 292(23):9745-9759, Elsevier, Netherlands (Jun. 2017). [cited by applicant]
Smith, E.J., et al., “A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys,” Sci. Rep. 5:17943, Nature Publishing Group, United … [cited by applicant]
Sondergeld, P., et al., “Monoclonal antibodies in myeloma,” Clin. Adv. Hermatol. Oncol. 13(9):599-609, Millennium Medical Publishing, United States (Sep. 2015). [cited by applicant]
Sonneveld, P., and Broji, A., “Treatment of relapsed and refractory multiple myeloma,” Haematologica. 101(4):396-404, Ferrata Storti Foundation, Italy (Apr. 2016). [cited by applicant]
Stutz, C., et al., “A single mutation increases heavy-chain heterodimer assembly of bispecific antibodies by inducing structural disorder in one homodimer species,” J. Biol. Chem. 295(28):9392-9408, Elsevier, Netherland… [cited by applicant]
Szlasa, W., et al., “Targeting CD38 in Neoplasms and Non-Cancer Diseases,” Cancers 14(17):4169, MDPI, Switzerland (Aug. 2022). [cited by applicant]
Tai, Y.T., et al., “Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu,” Blood. 113(4):1329-37, The American Soci… [cited by applicant]
Tandon, B., and Duncavage, E.J., “The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes,” Int. J. Lab. Hematol. 1:115-21, Wiley, United Kingdom (Ma… [cited by applicant]
Tomlinson, I., and Holliger, P., “Methods for generating multivalent and bispecific antibody fragments,” Methods Enzymol. 326:461-79, Elsevier, Netherlands (2000). [cited by applicant]
Uhlen, M., et al., “A pathology atlas of the human cancer transcriptome,” Science. 357(6352):eaan2507, American Association for the Advancement of Science, United States (Aug. 2017). [cited by applicant]
UniProtKB, “A0A2K5UD97_MACFA,” Accession No. A0A2K5UD97, accessed at https://www.uniprot.org/uniprotkb/A0A2K5UD97/, accessed on Jul. 6, 2023, 6 pages. [cited by applicant]
UniProtKB, “CD38_HUMAN,” Accession No. P28907, accessed at https://www.uniprot.org/uniprotkb/P28907, accessed on Jul. 6, 2023, 9 pages. [cited by applicant]
UniProtKB, “CD38_MACFA,” Accession No. Q5VANO, accessed at https://www.uniprot.org/uniprotkb/Q5VAN0/, accessed on Jul. 6, 2023, 6 pages. [cited by applicant]
UniProtKB, “CD3D_HUMAN,” Accession No. P04234, accessed at https://www.uniprot.org/uniprotkb/P04234/, accessed on Jul. 6, 2023, 12 pages. [cited by applicant]
UniProtKB, “CD3D_MACDA,” Accession No. Q95LI8, accessed at https://www.uniprot.org/uniprotkb/Q95LI8/, accessed on Jul. 6, 2023, 8 pages. [cited by applicant]
UniProtKB, “CD3E_HUMAN,” Accession No. P07766, accessed at https://www.uniprot.org/uniprotkb/P07766/, accessed on Jul. 6, 2023, 12 pages. [cited by applicant]
UniProtKB, “CD3E_MACFA,” Accession No. Q95LI5, accessed at https://www.uniprot.org/uniprotkb/Q95LI5/, accessed on Jul. 6, 2023, 8 pages. [cited by applicant]
UniProtKB, “CD3G_HUMAN,” Accession No. P09693, accessed at https://www.uniprot.org/uniprotkb/P09693, accessed on Jul. 6, 2023, 12 pages. [cited by applicant]
UniProtKB, “CD80_MOUSE,” Accession No. Q00609, accessed at https://www.uniprot.org/uniprotkb/Q00609/, accessed on Jul. 6, 2023, 10 pages. [cited by applicant]
UniProtKB, “TNR17_HUMAN,” Accession No. Q02223, accessed at https://www.uniprot.org/uniprotkb/Q02223/, accessed on Jul. 6, 2023, 8 pages. [cited by applicant]
Ward, E.S., et al., “Binding activities of a repertoire of single immunoglobulin variable domains secreted from [cited by applicant]
Wines, B.D., et al., “The interaction of Fc alpha RI with IgA and its implications for ligand binding by immunoreceptors of the leukocyte receptor cluster,” J Immunol. 166(3):1781-9, The American Association of Immunolo… [cited by applicant]
Zun De Zafra, C.L., et al., “Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release,” Clin Cancer Res. 25(13):3921-3933, Amer… [cited by applicant]